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Abstract Glioblastoma multiforme is the most common
type of primary brain tumor in adults. WWOX is a tumor
suppressor gene involved in carcinogenesis and cancer
progression in many different neoplasms. Reduced WWOX
expression is associated with more aggressive phenotype
and poor patient outcome in several cancers. We investi-
gated alternations of WWOX expression and its correlation
with proliferation, apoptosis and signal trafﬁcking in 67
glioblastoma multiforme specimens. Moreover, we exam-
ined the level of WWOX LOH and methylation status in
WWOX promoter region. Our results suggest that loss of
heterozygosity (relatively frequent in glioblastoma multi-
forme) along with promoter methylation may decrease the
expression of this tumor suppressor gene. Our experiment
revealed positive correlations between WWOX and Bcl2
and between WWOX and Ki67. We also conﬁrmed that
WWOX is positively correlated with ErbB4 signaling
pathway in glioblastoma multiforme.
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Introduction
Glioblastoma multiforme (GBM) is the most common type
of primary brain tumor in adults. This highly lethal neo-
plasm is particularly difﬁcult to treat due to its speciﬁc
features, i.e., poor permeability of blood–brain barrier, that
prevents chemotherapeutics from reaching their target, and
low ability of brain tissue to renew, that makes surgical
intervention very difﬁcult and venturesome. The major
molecular changes are well deﬁned and differentiate GBM
into primary and secondary tumor subtypes. The main
known alterations are LOH 10q, EGFR ampliﬁcation,
p16
INK4a deletion, PTEN and p53 mutations [1]. However,
the molecular basis of brain tumorigenesis still requires
further intensive study, since neoplastic transformation is
a complicated process resulting from both genetic and
epigenetic alterations of the genome.
The tumor suppressor gene WWOX is localized in a
common fragile site FRA16D (locus 16q23.3–24.1). Pro-
tein encoded by WWOX is an oxidoreductase containing
two WW protein interaction domains. The biological role
of the protein is not yet deﬁned, although there are sup-
positions that it may play a part in steroid hormones
metabolism and ErbB4 receptor signaling pathway [2, 3].
Modiﬁed expression of WWOX suppressor gene was
observed in many types of tumors [4–6]. Absence of point
mutations necessitates searching for other mechanisms
which can deregulate WWOX expression. Loss of hetero-
zygosity in WWOX locus was reported in many types of
cancer (breast, esophagus, and lungs, among others [7–9]).
Some authors observed a correlation between WWOX
promoter methylation status and its expression level
[10–13]. Promoter methylation is one of the key mecha-
nisms silencing tumor suppressor genes. It has been well
demonstrated that expression of genes such as p27 [14, 15],
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thylation in some cancer types.
Futile traditional methods of glioblastoma multiforme
treatment have provoked an intensive search for a better
understanding of molecular aberrations underlying the
formation and progression of this kind of cancer. The aim
of our experiments was to elucidate the role of the WWOX
suppressor gene in GBM. Here, we report on our investi-
gation into correlations between expression of WWOX and
genes involved in cellular functions such as proliferation
(Ki67), signal transduction (EGFR, ErbB4), and apoptosis
(Bax, Bcl2). Moreover, we assessed the methylation state
of WWOX promoter and examined the association between
methylation and expression level. Additionally, we evalu-
ated frequency of loss of heterozygosity in WWOX locus
and its inﬂuence on gene expression.
Materials and methods
Patients
The study included 67 cases of glioblastoma multiforme,
diagnosed according to the World Health Organization
criteria for classiﬁcation of brain tumors. The group con-
sisted of 20 females, 35 males and 2 not speciﬁed. The
patients’ mean age was 58.6 years (range 27–76). The
mean follow-up was 11.8 months (range 1–26).
Total RNA isolation, cDNA syntesis and DNA isolation
RNA was extracted from frozen brain tissues, stored at
-80C in RNAlater (Ambion), using TRIzol reagent
(Invitrogen). cDNA synthesis was performed from 10 lg
of total RNA at volume of 100 ll using ImProm RT-II
TM
reverse transcriptase (Promega). Reverse transcription was
carried out under the following conditions: incubation at
25C for 5 min and 42C for 60 min, heating at 70C for
15 min. cDNA samples were diluted with sterile deionized
water to a total volume of 150 and 2 ll was added to a PCR
reaction.
DNA was recovered from organic rests of TRIzol after
RNA isolation using manufacturer’s protocol.
Real-time RT–PCR analysis
Real-time RT–PCR was performed using Rotor-Gene
TM
3000 (Corbett Research). PCR products were detected
using SYBR
 Green I and qPCR Core kit for SYBR

Green I (Eurogentec). All reactions were performed in
duplicate. We analyzed relative expression level of 6 genes
(Bax, Bcl2, EGFR, Ki67, WWOX, ErbB4 isoforms JM-a
and JM-b). The expression levels of investigated genes
were normalized to three reference genes (RPS17, H3F3A,
and RPLP0).
Due toarelativelylowlevel ofWWOXmRNA, we useda
semi-nested RT–PCR for detection of WWOX expression
level. First, PCR reaction was performed with primers
50-TGCAACATCCTCTTCTCCAACGAGCTGCAC-30 and
50-TCCCTGTTGCATGGACTTGGTGAAAGGC-30 in 50 ll
reaction volume. Subsequently, 2 ll of 200-fold-diluted PCR
product (171 bp) was used as a template for semi-nested PCR.
The cycling protocol consists of: 2 min at 94C, 30 s dena-
turation at 94C, 30 s annealing at 63C, 1 min extension at
72Crepeatedfor77cycles,andadditionalextensionfor7 min
at 72C.
Sequences of primers, annealing and detection temper-
atures, and the length of products are presented in Table 1.
Relative gene expression was calculated with the Roche
guidebook according to a previously published algorithm
[19]. Universal Human Reference RNA (Stratagene)
composed of 10 cell lines was used as a calibrator.
All primers were designed to be intron-spanning to
avoid ampliﬁcation of genomic DNA. Detection tempera-
ture was determined above unspeciﬁc/primer-dimer
melting temperature.
LOH analysis
Loss of heterozygosity detection was performed using
‘‘high’’ resolution melting of Rotor-Gene
TM 3000 (Corbett
Research). Allelic losses were analyzed by PCR ampliﬁ-
cation with three sets of primers for microsatellites
D16S518 (intron 1 of WWOX gene), D16S3096 and
D16S504 (intron 8). The primer sequences were obtained
from the Genome database. PCR cycling programs inclu-
ded 1 cycle with 95C for 10 min followed by 35 cycles
consisting of 94C for 30 s, 56C (for D16S3096 and
D16S504) or 55C (for D16S518) for 30 s, 72C for 60 s.
MethylScreen
To assess the level of promoter methylation we preformed
the MethylScreen assay [20]. The method is based on a set
of restriction digestions coupled with subsequent real-time
PCR. DNA was isolated from frozen brain tumor tissue.
Next, 2 lg of DNA of every sample were divided into four
500-ng parts and each underwent different treatment. The
ﬁrst, called Mock, was a positive control, incubated with
digestion buffer, yet without addition of any enzymes. The
second was treated with two methylation-sensitive restric-
tion enzymes (MSRE), HhaI and HpaII (cutting only
unmethylated template). The third was incubated with
methylation-dependent restriction enzyme (MDRE),
McrBC (cutting only methylated DNA). The fourth, a
negative control, was simultaneously double digested with
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equivalent amounts of 19 NEB buffer 2 (10 mM Tris–
HCl, 55 mM NaCl, 10 mM MgCl2, 1 mM DTT), 1 lg/ml
bovine serum albumin (BSA), 2 mM guanosine-50-tri-
phosphate (GTP), water and appropriate enzymes. Diges-
tions were incubated for 4 h at 37C and then 20 min at
65C to halt enzyme activity. Following enzyme digestion,
samples were analyzed by real-time PCR using the
RotorGene 3000
TM system. Using locus-speciﬁc PCR
primers, intact genomic DNA was ampliﬁed, while geno-
mic DNA that had been cleaved by restriction endonucle-
ases was not. A change in the number of ampliﬁable loci
was detected in the ﬂuorescence cycle threshold among the
separate digests. Standard curve data was created for each
patient by setting the Mock positive control as 100 standard
and double digest negative control as 0.001 standard. The
threshold was set by maximizing the regression ﬁt to the
standard curve. The DNA sample was scored as methylated
if the difference between Mock and MSRE/MDRE diges-
tions Ct was[1.
Two sets of PCR primers were designed for the ampliﬁ-
cation of two genomic DNA fragments at the promoter and
ﬁrst exon of the WWOX gene. The PCR products were 384
and 413 bp long and contained %GC = 66.5. The forward
primersequencefortheﬁrst(-508to-174 bp)regionofthe
promoter was 50-ACAGAAGCCCAGGACAACAGCAT
GG-30, and the reverse primer sequence was 50-ACCAC-
GAAGCTGAAATCCAGTCTCCG-30. The forward primer
sequence for the second region (from –171 bp to ?239 bp)
was 50-AGACTGGATTTCAGCTTCGTGGTCG-30, and
the reverse primer sequence was 50-AAGCTCCTTAA-
CAGTTACTTTCACTTTGCAC-30.
For the WWOX distal promoter fragment, the reaction
mix consisted of 2.5 ll of SYBR
 Green I, qPCR Core kit
for SYBR
 Green I reagents (Eurogentec), 10 nM of each
primer, 4 ll of digested DNA template. Real-time PCR
Table 1 Real-time PCR reactions characteristics
Gene primers (50 ? 30) PCR product size (bp) Annealing temp. (C) Detection temp. (C)
H3F3A
AGGACTTTAAAAGATCTGCGCTTCCAGAG
ACCAGATAGGCCTCACTTGCCTCCTGC
76 65 72
RPLPO
ACGGATTACACCTTCCCACTTGCTAAAAGGTC
AGCCACAAAGGCAGATGGATCAGCCAAG
69 65 72
RPS17
AAGCGCGTGTGCGAGGAGATCG
TCGCTTCATCAGATGCGTGACATAACCTG
87 64 72
Bcl2
TTGGCCCCCGTTGCTTTTCCTC
TCCCACTCGTAGCCCCTCTGCGAC
122 56 81
Bax
AGAGGTCTTTTTCCGCGTGGCAGC
TTCTGATCAGTTCCGGCACCTTG
137 56 81
Ki67
TCCTTTGGTGGGCACCTAAGACCTG
TGATGGTTGAGGCTGTTCCTTGATG
156 56 81
WWOX
GAGCTGCACCGTCGCCTCTCCCCAC
TCCCTGTTGCATGGACTTGGTGAAAGGC
150 63 77
EGFR
AGCTTCTTGCAGCGATACAGCTCAGAC
TGGGAACGGACTGGTTTATGTATTCAGG
106 58 81
JM-a ErbB4
ACACAGCCCTCCTCCTGCCTACAC
AGGGCACAGACACTCCTTGTTCAGC
95 56 76
JM-b ErbB4
AGAGCAAGAATTGACTCGAATAGGAACC
AGGGCACAGACACTCCTTGTTCAGC
82 56 76
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followed by 50 cycles at 94C for 30 s, 55C for 30 s, and
72C for 90 s, and 77C for 15 s. Fluorescence reading was
performed after each cycle at 77C. For the second WWOX
promoter fragment (covering the 30 end of the promoter and
part of exon 1), the reaction mix consisted of 2.5 llo f
SYBR
 Green I, qPCR Core kit for SYBR
 Green I
reagents, 10 nM of each primer, 4 ll of digested DNA
template, and 70 mM of betaine. Real-time PCR was
conducted at the following conditions: 95C for 5 min,
followed by 50 cycles at 94C for 30 s, 50C for 30 s, and
72C for 90 s, and 83C for 15 s. Fluorescence reading was
performed after each cycle at 83C.
Statistical analysis
Correlation analysis between the expression levels of
WWOX and other genes and clinical factors was performed
using non-parametric Spearman Rank Correlation test.
Differences between transcription level of WWOX gene in
relation to its methylation status, LOH and patients’ sex
were estimated by Student’s t test. All results were rec-
ognized statistically signiﬁcant at conﬁdence level[95%
(P\0.05).
Results
The methylation analysis of 61 GBM tissue samples
revealed that the ﬁrst, distal fragment of WWOX promoter
was methylated in 18% (11 of 61) of cases, while the
second, nearby TATA box in 15% (9 of 61). Further
analyses revealed that methylation state of the distal pro-
moter region had no inﬂuence on WWOX expression.
Hence, to clarify the presentation, it has been excluded
from further consideration in the current report. The mean
WWOX expression level in samples with methylated sec-
ond promoter fragment was noticeably lower than in
unmethylated (11.71 vs 21.93; P = 0.15), although this
difference was not statistically signiﬁcant in the Aspin–
Welch mean test. The medians were 6.23 for methylated
and 12.04 for unmethylated samples (P = 0.23). Despite
the absence of statistical signiﬁcance in the obtained
results, there was a noticeable tendency of promoter
methylation to lower WWOX gene expression.
We observed a relatively high percentage of LOH for
two out of three analysed microsatellites. The level of
hemizygosity was D16S3096 (38.5%) and D16S504
(54.5%) which is signiﬁcantly higher than homozygosity
observed in the population. The two microsatellites are
located adjacent to the end of WWOX gene, in intron 8. The
details of the LOH analysis are presented in Table 2.
Statistical analysis revealed no correlation between LOH
and reduction of WWOX expression. In D16S3096, mean
WWOX expression was 18.84 for heterozygous samples
and 24.91 for homozygous (P = 0.63). The medians were
12.81 and 8.97, respectively (P = 0.58). For the D16S504
microsatellite marker, these values were: means 26.94
versus 15.25 (P = 0.24) and medians 9.78 versus 10.9
(P = 0.71).
We also analyzed the WWOX expression level concur-
rently with reference to promoter methylation and micro-
satellite markers state. This revealed a difference in WWOX
expression in homo- and heterozygotes, which was not
noticeable in the summary analysis without considering
methylation state. The highest expression was demon-
strated by unmethylated, heterozygous samples, while the
lowest by methylated, homozygous samples. Loss of het-
erozygosity lowered expression levels in unmethylated
samples (with the exception of D15S504). Promoter
methylation considerably reduces WWOX expression both
in hetero- and homozygous cases. The details are presented
in Table 3.
In an experiment on 67 patients with GBM, we noticed a
positive correlation between expression level of WWOX
suppressor gene and marker of proliferation Ki67
(Rs = 0.5440; P\0.0001). Correlation analysis of WWOX
gene expression level with apoptotic pathway revealed a
positive association with antiapoptotic gene Bcl2 mRNA
level (Rs = 0.7092; P\0.0001) but not with proapoptotic
Bax mRNA level and Bcl2/Bax ratio (P[0.05). Further-
more, there was a positive correlation with transcription
level of WWOX and JM-a isoform of ErbB4. We did not
ﬁnd any statistically signiﬁcant association between
WWOX and EGFR expression level (P[0.05), or between
WWOX and JM-b isoform of ErbB4 (P[0.05). The
analysis of expression correlation between WWOX and
other investigated genes is presented in Table 4.
There was no correlation between WWOX expression
and factors such as age, sex and time of survival.
Discussion
LOH
Lowered expression level of the WWOX gene has been
observed in many types of cancer [8, 9, 11, 12, 21–27].
Among other possibilities, the reason might be the loss of
heterozygosity or epigenetic changes such as methylation
of CpG islands in promoter region. Several researchers
have revealed LOH of WWOX locus in gastric [21], pan-
creatic [12], esophageal [8] and lung [9] cancer. In our
study on GBM, we noticed no LOH in WWOX intron 1
(observed hemizygosity and populational homozygosity
were nearly the same) and relatively frequent incidence of
210 J Neurooncol (2011) 101:207–213
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did not observe a correlation of LOH with WWOX
expression level, adding data on promoter methylation state
to our analysis allowed us to observe such a connection.
That indicates that loss of heterozygosity concurrently with
promoter methylation affects the expression of WWOX
gene in glioblastoma multiforme.
Promoter methylation
Hypermethylation of gene regulatory regions is a common
event in cancer cells. In most cases, promoter methylation
reduces or completely silences affected gene expression.
WWOX promoter methylation has been reported to be a
possible cause of reducing WWOX expression in breast,
lung, bladder, pancreas and prostate cancers [10, 12, 13].
As shown in our experiment, methylation of the WWOX
promoter region in the examined GBM samples was
infrequent: 18% for the distal and 15% for the nearby
TATA box promoter fragment. If it occurred, methylation
slightly correlated with reduction of WWOX mRNA level,
although the difference in mean expression for methylated
and unmethylated samples was not statistically signiﬁcant,
probably because of the small number of methylated
samples (11 and 9 of 61). Nevertheless, a tendency of
WWOX promoter methylation to reduce its expression can
be seen.
Expression correlations
Numerous authors have shown signiﬁcant dependence of
recurrence and drug resistance on alterations of the apop-
tosis pathway in glioma tumors. In patients with GBM, up-
regulation of antiapoptotic genes Bcl2, Bcl-xl, MCL-1 and
down-regulation of proapoptotic Bax gene were associated
with recurrence of the disease [28]. Other authors have
demonstrated that increasing the Bcl2 protein level corre-
lates with higher grading in the glioma tumor cell line [29].
Moreover, up-regulation of antiapoptotic Bcl-xl gene with
concurrent overexpression of EGFRvIII can be a cause of
resistance to cisplatin agent [30]. Usage of Bcl2 speciﬁc
antisense oligonucleotides activates apoptosis and may be
helpful in treatment [31]. In our study, we found a positive
correlation between expression of WWOX and the antiap-
optotic gene Bcl2. However, we did not observe any con-
nection of WWOX expression either with proapoptotic Bax
gene expression or with a Bcl2/Bax ratio. These results are
consistent with previously reported breast cancer analysis
[32]. Interestingly, in vitro experiments conducted on
MDA-MB-231 breast cancer cell line showed elevated
apoptosis immediately after transfection with vectors har-
boring WWOX cDNA [33], though the stable transfectants
showed elevated Bcl2 expression level, induced migration
in Matrigel, and invasion through basal membrane, but
inhibition of anchorage-independent growth [34]. Ovarian
cancer cell lines showed similar behavior when transfected
with WWOX cDNA; apoptosis was induced in cells
growing in suspension but not in adherent cells [35].
Additionally, we found that WWOX expression was
positively correlated with Ki67 mRNA level, considered as
a marker of cell proliferation. A similar correlation of
WWOX and Ki67 was observed in breast cancer samples
[32]. Analysis of proliferation in ovarian cancer cell lines
transfected with WWOX cDNA showed no correlation of
Table 2 An analysis of LOH in WWOX region
D16S518 (%) D16S3096 (%) D16S504 (%)
Observed hemizygosity in GBM 18 38.5 54.5
Populational homozyogosity
a 17 26 36.7
Predicted loss of heterozygosity 1 12.5 19.8
a From Genome database
Table 3 Median WWOX expression in LOH and promoter methyla-
tion status differing subgroups
D16S518 D16S3096
Heterozygous, unmethylated 12.69 13.17
Heterozygous, methylated 6.63 6.23
Hemizygous, unmethylated 7.32 9.37
Hemizygous, methylated 5.66 5.85
The differences between the subgroups’ median WWOX expression
were statistically insigniﬁcant
Table 4 Spearman rank correlation between WWOX expression level
and other tumour related genes
Gene Correlation
coefﬁcient Rs
P
EGFR 0.2413 NS (0.0611)
ErbB4 JM-a 0.7102 \0.0001
ErbB4 JM-b 0.2108 NS (0.1029)
Ki67 0.5440 \0.0001
Bax 0.2301 NS (0.0745)
Bcl2 0.7092 \0.0001
Bcl2/Bax 0.1995 NS (0.1442)
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of experiments which have proved that there is no associ-
ation between Ki67 and factors such as age, Karnofsky
index, and survival in human glioblastoma. However, there
is a positive correlation with p53 expression [36, 37]. There
was no connection observed between proliferation activity
in cells of anaplastic glioma with other molecular prolif-
eration markers such as p16, Rb, EGFR [37]. Nevertheless,
Ki67 exhibited statistically signiﬁcant differences in
staining between the tumor types of astrocytoma, ana-
plastic astrocytoma, and glioblastoma [38]. The prognostic
value of Ki67 in glioblastoma multiforme is currently
strongly controversial [36, 39].
Unfortunately, we have less than 50% patient survival,
tumor size and localization data, and therefore we were
unable to perform reliable survival analysis.
WWOX involvement in ErbB4 signalling pathways
Two ErbB4 splice isoforms differ in a short juxtamem-
brane sequence. JM-a form is prone to sequential proteo-
lytic cleavage conducted by tumor necrosis factor a
converting enzyme (TACE) and c-secretase. That intra-
membranous proteolysis releases intracellular domain
(ICD) which might be translocated to the nucleus, where it
transactivates genes expression [40]. As was shown by
Aqeilan et al., ErbB4 might be regulated by the WWOX
tumor suppressor protein [2, 41]. The WWOX-ErbB4
interaction occurs with both full-length membrane-
anchored ErbB4 and cleaved ICD fragment. When asso-
ciated to uncleaved ErbB4, WWOX stabilizes the receptor
in cellular membrane. Linked with ICD, WWOX prevents
it from reaching the nucleus. The YAP protein has an
opposite effect on ICD function. It facilitates ICD trans-
location to the nucleus and gene activation. Probably, YAP
and WWOX compete for association with ICD fragment
[41]. JM-b splice variant of ErbB4 harbors changes in a
short sequence containing the cleavage site and is resistant
to proteolytic enzymes activity. There is no evidence of
WWOX association with JM-b. Our results showed a
functional difference between JM-a and JM-b isoforms.
While JM-a expression strongly correlated with WWOX
(R = 0.7102), which is consistent with breast cancer
results obtained by Aqueilan et al. [2], JM-b did not show
such a correlation. As shown elsewhere [41], WWOX
associates with two PPxY motifs of JM-a by its ﬁrst WW
domain. Subcellular localization of transcription cofactors
is one of the major ways to regulate gene expression
activation. Our study conﬁrmed that WWOX is an impor-
tant player in the ErbB4 signaling pathway although details
of its action still wait to be revealed. The mechanism of the
WWOX tumor suppressor function is not explained, but it
seems that interactions with ErbB4 receptor might be one
element.
Conclusion
Our study indicated that genomic deletions in the 30 end of
the WWOX gene occurs with high frequency in glioblas-
toma multiforme. LOH correlates with reduction of WWOX
expression. Although without statistical conﬁrmation, our
results suggest that promoter methylation may also differ-
entiate expression of WWOX. Moreover, WWOX tran-
scription in GBM is strongly associated with proliferation
and apoptosis, and is involved in a signal transduction
through the ErbB4 pathway. WWOX genetic alternations
and expression correlation with other cancer-related genes
in GMB are similar to those observed in breast and ovarian
cancer. Therefore, WWOX gene inactivation seems to play
an important role in GBM carcinogenesis.
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